|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
ͺ�� |
|
���� |
| ��������������� | |
|
������ |
|
�ź� |
| PubMed | |
|
Article by |
|
Article by |
�ۼ���Դ���ѷ�������ѧ��չ
������, �ź�
���ϴ�ѧ������һҽԺƤ���� ���� 510632
�ۼ���Դ���ѷ��������һ���ѷ�,���ܶ�����Ӱ��,������,������Ч����,�Ը������û��Ʋ�ͬ��ҩ�ë����ֲ������ϸ����������֬����ë�Ҵ���ϵͳ���������Ƶ��������ۼ���Դ���ѷ��е�Ӧ�á���Ч��������Ӧ�о���չ���˸�����
�㶫ʡ�Ƽ��ƻ���Ŀ(���Ƽ���281)
[2] Finasteride Male Pattern Hair Loss Study Group. Long-term (5-year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia. Eur J Dermatol, 2002,12:38-49.
[3] Lin JH, Chen WC. Finasteride in the treatment of Taiwanese men with androgenetic alopecia: a 12-month open-label study. Kaohsiung J Med Sci, 2002,8:379-335.
[4] Tosti A, Piraccini BM, Soli M. Evaluation of sexual function in subjects taking finasteride for the treatment of androgenetic alopecia. J Eur Acad Dermatol Venereol, 2001,15:418-421.
[5] Price VH. Treatment of hair loss. N Engl J Med, 1999,341:964-973.
[6] Sintov A, Serafimovich S, Gilhar A. New topical antiandrogenic formulations can stimulate hair growth in human bald scalp grafted onto mice. Int J Pharn, 2000, 194:125-134.
[7] Vierhapper H, Maier H, Nowotny P,et al. Production rates of testosterone and of dihydrotestosterone in female pattern hair loss. Metabolism, 2003, 52:927-929.
[8] Vexiau P, Chaspoux C, Boudou P,et al. Role of androgens in femalepattern androgenetic alopecia, either alone or associated with other symptoms of hyperandrogenism. Arch Dermatol Res, 2000, 292:598-604.
[9] Carmina E, Lobo RA. Treatment of hyperandrogenic alopecia in women. Fertil Steril, 2003,79:91-95.
[10] Sovak M, Seligson AL, Kucerova R, et al. Fluridil, a rationally designed topical agent for androgenetic alopecia: first clinical experience. Dermatol Surg, 2002,28:678-685.
[11] Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for androgenetic alopecia. American Academy of Dermatology. J Am Acad Dermatol, 1996,35:465-469.
[12] Hoffmann R,Niiyama S, Huth A, et al. 17alpha-estradiol induces aromatase activity in intact human anagen hair follicles ex vivo. Exp Dermatol, 2002,11:376-380.
[13] Otomo S. Hair growth effect of minoxidil. Nippon Yakurigaku Zasshi,2002,119:167-174.
[14] Vexiau P,Chaspoux C, Boudou P,et al. Effects of minoxidil 2% vs.cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12-month randomized trial. Br J Dermatol, 2002,146:992-999.
[15] Olsen EA, Dunlap FE, Funicella T, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical ninoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol,2002,47:377-385.
[16] Unger WP, David LM. Laser hair transplantation. J Dermatol Surg Oncol. 1994,20:515-521.
[17] Sadick NS, Shea CR, Nicholson J, et al. A comparative clinical and histologic study of hair transplantation using Er: YAG, Er: YAG/CO2,and standard punch techniques. Dermatol Surg, 2001,27:807-812.
[18] Sadick N. Elliptografting: the right fit. Dernatol Surg, 2001,27:739-743.
[19] Tsai RY, Lee SH, Chan HL,et al. The distribution of follicular units in the Chinese scalp: implications for reconstruction of natural-appearing hairlines in Orientals. Dermatol Surg, 2002,28:500-503.
[20] Avram MR, Cole JP, Gandelman M, et al. The potential role of minoxidil in the hair transplantation setting. Dermatol Surg, 2002,28:894-900.
[21] Lindenbaum ES, Feitelberg AL, Tendler M. Pilot study of a novel treatment for androgenetic alopecia using enriched cell culture medium: clinical trials. Dermatol Online J, 2003,9:4.
[22] Lin L,Hoffman RM. Topical liposome delivery of molecules to hair follicles in mice. J Dermatol Sci, 1997,14:101-108.
[23] Domashenko A, Gupta S, Cotsarelis G. Efficient delivery of transgenes to human hair follicle progenitor cells using topical lipoplex. Nat Biotechnol, 2000,18:420-423.